The first case of BF.7 local new crown infection has appeared in Hohhot, China, and triggered a local epidemic

The new crown omirion mutation strain has
mutated again.
The first case of BF.
7 local new crown infection has appeared in Hohhot, China, and triggered a local epidemic
.

On October 6, Jimu News reporter noticed that as early as September 23, the British "Coventry Telegraph" had reported that the new mutant strain BF.
7 was spreading
rapidly in Belgium, Germany, France, Denmark and the United States.
The World Health Organization has warned that BF.
7 may become the global mainstream
within a few weeks.

A nurse injects COVID-19 vaccine into a syringe (Image: Coventry Telegraph)

There have been BF.
7 new coronavirus infections in China

According to Health Times, on September 28, Hohhot, Inner Mongolia Autonomous Region, reported a case of local new crown pneumonia infection, after national genetic sequencing testing, the case belongs to the new crown virus Omicraon mutation strain BF.
7 evolutionary branch, which is the first time that the branch has caused a local epidemic
in China.
As of October 3, more than 500 cases of infection with this mutant strain in Inner Mongolia Autonomous Region have been reported in six days
.

Jimu News reporter noted that the number of infection cases in the Inner Mongolia Autonomous Region is still increasing
.
From September 28 to October 5, the Inner Mongolia Autonomous Region reported a cumulative total of 1,258 cases of local infection for eight consecutive days
.

What are the properties of the new variant strain, BF.
7? Wang Yuge, a vaccine researcher at Omichron, a researcher at the National Institutes of Health and a doctor of immunology, told the People's Daily Health Client reporter that BF.
7 is essentially an OmicronBA.
2 lineage virus
.
From BA.
2 to BA.
5 to BF.
7, new mutants continue to "roll in", the virus transmission is increasing, and the ability to evade immunity is getting stronger and stronger
.

The Shaanxi CDC interpreted the BF.
7 mutant strain, and the symptoms of the mutant after infection included high fever, persistent cough, body pain, headache, sore throat, changes in smell and loss of
appetite.

"Patients who have been infected with BA.
5 are still at risk of
being infected with BF.
7.
" Wang Yuge further explained that BF.
7 adds the receptor-binding domain RBD mutation R346T to BA.
4/5, which can further escape the neutralizing antibody
induced by BA.
5 infection.
Therefore, it has the potential to become a mutant strain
that will become popular this autumn or winter.

It has previously spread rapidly in many countries around the world

The Coventry Telegraph reported on 23 September that the new variant strain, BF.
7, which has been detected, is spreading rapidly in several countries, where it now accounts for a
quarter of new cases.

According to statistics, the new variant BF.
7 accounts for 25% of new coronavirus cases in Belgium and 10%
of cases in Germany, France and Denmark.
To date, the UK has seen hundreds of cases
of new variant strains of BF.
7.
In the United States, where new cases are also increasing rapidly in just a few days, it is more transmissible
than BA.
5.

Statistics from the U.
S.
Centers for Disease Control and Prevention show that in the past two weeks, the incidence of new variants of BF.
7 has doubled across the country, from 0.
8 percent to 1.
7 percent
.
The website said that this proves that the US government's concerns about the future epidemic are justified
.

"It's been a while since Alpha to Beta to Gamma to Delta and then to Omicron, and we may be complacent and feel like COVID-19 is over
.
" An expert in the Johns Hopkins University Department of Medicine admitted that the new crown will not disappear
.
He analyzed variant growth in different countries and concluded that "BF.
7 is gaining a foothold
.
" ”

The World Health Organization has also warned that BF.
7 is spreading globally and "may become mainstream in a matter of weeks"
.

The current COVID-19 response remains valid

Several experts said the current plan to fight COVID-19 remains effective
.

Zhu Fengcai, a WHO new crown vaccine priority review expert and deputy director of the Jiangsu Provincial Center for Disease Control and Prevention, told the People's Daily Health Client reporter that the breakthrough infection has always existed, and the situation of
re-infection with the new crown also exists.
And although BF.
7 transmission has increased, it is mostly
asymptomatic patients and mild patients.

Not only vaccines, but COVID-19 drugs should also be effective
against the variant BF.
7.
Jiang Jiandong, academician of the Chinese Academy of Engineering and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, told the People's Daily Health Client reporter that the main target of the new crown small molecule drug is viral replicase, and at present, the relevant drug binding target site has not found mutations on Omikeron, so the impact on small molecule drugs should be small
.
Azivudin is effective against current circulating strains from real-world clinical data collected
.